U.S. Health Officials Accuse AstraZeneca of Misrepresenting Efficacy Data
image

Britain’s Competition and Markets Authority (CMA) has started its investigation into whether AstraZeneca’s takeover of Alexion Pharmaceuticals can reduce competition for products and services in the United Kingdom or any other markets.

The British competition regulator invites comments on the transaction from any interested party to assist the CMA with the assessment.

The comments should be reached by June 3.

In December 2020, British drug manufacturer AstraZeneca agreed to buy Alexion Pharmaceuticals for 175 dollars per share in cash and stock, valuing the Boston-based company at 39 billion dollars.

image

You may be interested

How troops wiped out ISWAP terrorists in Borno
News
5 views
News
5 views

How troops wiped out ISWAP terrorists in Borno

Webby - June 21, 2021

The Nigerian Air Force (NAF) on Sunday disclosed that joint operations between the ground and the air troops led to…

News
5 views

Vicious ISWAP commander killed in airstrike

Webby - June 21, 2021

[unable to retrieve full-text content]

Outlawed Yansakai Killing/Maiming People In Zamfara State
News
News

Outlawed Yansakai Killing/Maiming People In Zamfara State

Webby - June 20, 2021

/* custom css */ .tdi_59.td-a-rec{ text-align: center; }.tdi_59 .td-element-style{ z-index: -1; }.tdi_59.td-a-rec-img{ text-align: left; }.tdi_59.td-a-rec-img img{ margin: 0 auto 0…

Leave a Comment

Your email address will not be published.